Objective: to evaluate the application value of combined use of glucocorticoid and terbutaline in the treatment of patients with chronic obstructive pulmonary disease (COPD). Methods: during the study period, a certai...Objective: to evaluate the application value of combined use of glucocorticoid and terbutaline in the treatment of patients with chronic obstructive pulmonary disease (COPD). Methods: during the study period, a certain number of subjects were selected from June 2018 to June 2019, and all patients were hospitalized with confirmed COPD. After being selected as required, 100 cases were very suitable, and were grouped according to the treatment order number. Among them, 50 cases were placed in the control group for routine treatment during hospitalization, while the other 50 cases were placed in the observation group for combined medication of glucocorticoid and terbutaline during hospitalization. After continuous treatment in each group, the improvement of symptoms and the changes of related indicators were observed, and the curative effect and related indicators were statistically compared after the end. Results: from the comparison of the therapeutic effect, it was found that the observation group was higher than the control group, and the significant difference could be seen from p < 0.05. From the comparison of lung function, it was found that the values of each index in the observation group were greater than those in the control group, and the large difference in comparison could be seen from p < 0.05. From the comparison of blood gas function, it is found that each value in the indexes of the observation group is better than that of the control group, and the large contrast difference can be seen from p < 0.05. From the comparison of inflammatory factor index, it is found that each value in the index of the observation group is smaller than that of the control group, and it can be seen from p < 0.05 that the comparison difference is large. From the comparison of the quality of life index, we found that the values of each index in the observation group were greater than those in the control group, and we can see that the contrast difference was significant from p < 0.05. Conclusion: through the treatment of COPD patients for a period of time, and the use of glucocorticoid combined with terbutaline treatment, not only can effectively alleviate the symptoms of dyspnea, but also can ease the condition of COPD patients, so it has certain promotion value.展开更多
文摘Objective: to evaluate the application value of combined use of glucocorticoid and terbutaline in the treatment of patients with chronic obstructive pulmonary disease (COPD). Methods: during the study period, a certain number of subjects were selected from June 2018 to June 2019, and all patients were hospitalized with confirmed COPD. After being selected as required, 100 cases were very suitable, and were grouped according to the treatment order number. Among them, 50 cases were placed in the control group for routine treatment during hospitalization, while the other 50 cases were placed in the observation group for combined medication of glucocorticoid and terbutaline during hospitalization. After continuous treatment in each group, the improvement of symptoms and the changes of related indicators were observed, and the curative effect and related indicators were statistically compared after the end. Results: from the comparison of the therapeutic effect, it was found that the observation group was higher than the control group, and the significant difference could be seen from p < 0.05. From the comparison of lung function, it was found that the values of each index in the observation group were greater than those in the control group, and the large difference in comparison could be seen from p < 0.05. From the comparison of blood gas function, it is found that each value in the indexes of the observation group is better than that of the control group, and the large contrast difference can be seen from p < 0.05. From the comparison of inflammatory factor index, it is found that each value in the index of the observation group is smaller than that of the control group, and it can be seen from p < 0.05 that the comparison difference is large. From the comparison of the quality of life index, we found that the values of each index in the observation group were greater than those in the control group, and we can see that the contrast difference was significant from p < 0.05. Conclusion: through the treatment of COPD patients for a period of time, and the use of glucocorticoid combined with terbutaline treatment, not only can effectively alleviate the symptoms of dyspnea, but also can ease the condition of COPD patients, so it has certain promotion value.
